- Home
- UHS vs QGEN Comparison
UHS vs QGEN Comparison
Compare UHS & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHS
- QGEN
- Stock Information
- Founded
- UHS 1978
- QGEN 1986
- Country
- UHS United States
- QGEN Netherlands
- Employees
- UHS N/A
- QGEN N/A
- Industry
- UHS Hospital/Nursing Management
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UHS Health Care
- QGEN Health Care
- Exchange
- UHS Nasdaq
- QGEN Nasdaq
- Market Cap
- UHS 13.4B
- QGEN 10.7B
- IPO Year
- UHS N/A
- QGEN 1996
- Fundamental
- Price
- UHS $228.99
- QGEN $43.42
- Analyst Decision
- UHS Buy
- QGEN Buy
- Analyst Count
- UHS 13
- QGEN 7
- Target Price
- UHS $231.62
- QGEN $50.68
- AVG Volume (30 Days)
- UHS 619.5K
- QGEN 1.2M
- Earning Date
- UHS 10-27-2025
- QGEN 11-04-2025
- Dividend Yield
- UHS 0.35%
- QGEN 3.47%
- EPS Growth
- UHS 39.76
- QGEN 331.20
- EPS
- UHS 21.01
- QGEN 1.84
- Revenue
- UHS $16,992,503,000.00
- QGEN $2,070,781,000.00
- Revenue This Year
- UHS $10.41
- QGEN $7.37
- Revenue Next Year
- UHS $4.93
- QGEN $5.65
- P/E Ratio
- UHS $10.91
- QGEN $23.69
- Revenue Growth
- UHS 10.21
- QGEN 5.32
- 52 Week Low
- UHS $152.33
- QGEN $37.63
- 52 Week High
- UHS $229.76
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- UHS 72.18
- QGEN 29.66
- Support Level
- UHS $215.64
- QGEN $43.26
- Resistance Level
- UHS $227.22
- QGEN $47.39
- Average True Range (ATR)
- UHS 6.68
- QGEN 1.09
- MACD
- UHS 0.98
- QGEN -0.60
- Stochastic Oscillator
- UHS 97.33
- QGEN 8.86
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).